IngredientsXanthine (3,7-dihydro-1H-purine-2,6-dione) is a purine base that occupies a central position in the biochemistry of all living organisms. Xanthines (1H-purine-2,6(3H,7H)-diones) are purine-based natural heterocyclic alkaloids. The compound's systematic IUPAC name is 3,7-dihydro-purine-2,6-dione, and it is also recorded under synonyms including 2,6-dioxopurine, 2,6-dihydroxypurine, 9H-purine-2,6(1H,3H)-dione, pseudoxanthine, and xanthin. Its molecular formula is C₅H₄N₄O₂, with a molecular weight of 152.11 g/mol, and its CAS Registry Number is 69-89-6.
Xanthine is a purine base that is an antecedent of uric acid and is generally found in muscle tissue, blood, urine, and some plants. In its pure form, it is a water-insoluble, yellowish-white powder soluble in caustic soda; it sublimes when heated. The structure of xanthine consists of two rings — one six-membered ring and one five-membered ring. The structural resemblance with two of the important purine derivatives adenine and guanine makes xanthine a therapeutically significant molecule.
The xanthine alkaloids — caffeine, theobromine, and theophylline — are closely related compounds found in a variety of plants indigenous to several continents. They are not true alkaloids, as they are only weakly basic and possess some acidic properties. Their structural formulas include a purine ring, as found in the adenine and guanine nucleotides of DNA. The placement of the N-methyl groups determines the specific pharmacological profile of each compound.
Methylxanthines are a group of substances derived from the purine base xanthine, with a methyl group at the nitrogen at position 3 and different residues at the nitrogen at positions 1 and 7. The most well-known methylxanthines are caffeine (1,3,7-trimethylxanthine), theophylline (1,3-dimethylxanthine), and theobromine (3,7-dimethylxanthine).
Xanthine was obtained from urinary calculi in 1817. The compounds were first discovered in 1817 by German chemist Emil Fischer, and the name "xanthine" was coined in 1899. The early 19th century was the beginning of the isolation and characterization of many important plant alkaloids, including xanthine (1817), atropine (1819), quinine (1820), and caffeine (1820). In 1881 and 1882, Fischer published papers which established the formulae of uric acid, xanthine, caffeine (achieving the first synthesis), theobromine, and some other compounds of this group.
Under the umbrella of the purine family, xanthines are considered a point of convergence because both adenine and guanine converge during metabolism at this common intermediate. Xanthine and its derivatives act as intermediate molecules in the generation of GMP, GDP, and GTP via the salvage pathway inside cells, and xanthine plays an imperative role in the catabolism of nucleotides and nucleic acids, acting as a precursor of uric acid.
Remarkably, xanthine has even been detected beyond Earth: in August 2011, a report based on NASA studies with meteorites found on Earth was published suggesting that xanthine and related organic molecules, including the DNA and RNA components adenine and guanine, were found in outer space.
The natural sources of xanthine and its derivatives are plants such as tea, coffee, and cocoa seeds. As a free base, xanthine itself is present in muscle tissue, blood, and urine of mammals and in trace quantities in various plants. Its pharmacologically active methylated derivatives are the more practically encountered forms in nature. Methylxanthines, alkaloids derived from purine nucleotides, are present in various plants such as coffee (Coffea arabica), tea (Camellia sinensis), cacao (Theobroma cacao), kola (Cola acuminata), guarana (Paullinia cupana), and yerba mate (Ilex paraguariensis).
More than 60 plant species throughout the world have been identified as containing caffeine; the more common are from the genera Coffea, Camellia, Cola, Paullinia, Ilex, and Theobroma. With regard to the distribution of specific methylxanthines: unlike coffee, chocolate is enriched in theobromine, and the level of theophylline is quite low in both cacao and coffee. Theophylline is found in black tea and to a lesser extent in green coffee, cocoa cotyledon, and dried mate. Theobromine is the principal alkaloid of the cacao bean and is extracted from the bean husks, where it is also used in the synthesis of caffeine.
Within the human and mammalian body, xanthine arises endogenously through purine catabolism. Biologically, xanthine is produced from guanine by cypin (guanine deaminase). Xanthine is involved in purine degradation and is converted from hypoxanthine, and in turn is converted to uric acid by xanthine oxidase. Additionally, even without dietary intake, theobromine may occur in the body as it is a product of the human metabolism of caffeine, which is metabolized in the liver into 12% theobromine, 4% theophylline, and 84% paraxanthine; in the liver, theobromine is further metabolized into xanthine and subsequently into methyluric acid.
Although xanthine itself has no history of deliberate isolation and use in traditional medicine — its identity and structure remaining unknown to pre-modern practitioners — the xanthine-containing plants that deliver its pharmacologically active methylated derivatives have millennia-long histories of cultural and medicinal use across multiple civilizations.
Among these alkaloids, xanthine and its natural derivatives occupy a prominent place in traditional medicine. Natural xanthine derivatives such as caffeine, theophylline, and theobromine are purine-based nitrogenous compounds that possess medicinal properties that have been exploited in broad ways. The widespread natural occurrence of purine alkaloids — caffeine and other methylxanthines such as theobromine and theophylline — in a variety of plants undoubtedly played a major role in the long-standing popularity of caffeine-containing products, especially non-alcoholic beverages and foods (coffee, tea, soft drinks, cocoa, and chocolate products).
Coffee (Coffea arabica, native to Africa), tea (Camellia sinensis, native to China), and cacao (Theobroma cacao, native to South and Central America) have been cultivated and consumed for stimulant, restorative, and ceremonial purposes for centuries. These compounds are widely consumed in nutrition and used as pharmaceuticals. Theophylline, the methylxanthine of tea, was among the earliest treatments recognized for respiratory complaints. Theophylline was first extracted from tea leaves in 1888 by German biologist Albrecht Kossel.
Theobromine from cacao was recognized in formal science in the 19th century: theobromine was discovered in 1841 in cacao beans by chemist A. Woskresensky; synthesis of theobromine from xanthine was first reported in 1882 by Hermann Emil Fischer. Early industrial and pharmaceutical use included: most of the caffeine produced in the USA prior to 1945 was obtained by methylation of theobromine extracted from cocoa.
The xanthine family encompasses the parent molecule and a broad range of naturally occurring and synthetic methylated derivatives, each with distinct pharmacological profiles.
Caffeine (1,3,7-trimethylxanthine) is the major methylxanthine in foods, followed by theobromine (3,7-dimethylxanthine), and, more scarcely, theophylline (1,3-dimethylxanthine). Estimated population intakes have been documented: total per-caput intake of methylxanthines was estimated to be 233.79 mg/day in the USA in 1980, of which 194.6 mg (83.2%) were from caffeine, 39.05 mg (16.7%) from theobromine, and 0.14 mg (0.1%) from theophylline.
Xanthine is a mandatory intermediate in the catabolism of purines in all humans. Xanthine oxidoreductase (XOR) is the rate-limiting enzyme that catalyzes the oxidative hydroxylation of hypoxanthine to xanthine, and xanthine to uric acid. XOR is transcribed and translated as xanthine dehydrogenase (XDH) and can be posttranslationally converted to xanthine oxidase (XO).
Xanthine oxidoreductase (XOR) is a ubiquitous complex cytosolic molybdoflavoprotein that controls the rate-limiting step of purine catabolism by converting xanthine to uric acid. It is known that optimum concentrations of uric acid and reactive oxygen species are necessary for normal functioning of the body. The ability of XOR to perform detoxification reactions and to synthesize uric acid and reactive oxygen species makes it a versatile intra- and extra-cellular protective "housekeeping enzyme." It is also an important component of the innate immune system.
The mammalian form of this enzyme exists in two interconvertible forms, xanthine dehydrogenase (XDH) and xanthine oxidase (XO), with XDH as the predominant form in normal healthy tissue. XDH preferably uses NAD⁺ as an electron acceptor, while XO uses O₂ as the terminal electron acceptor, thereby exhibiting the ability to generate reactive oxygen species (ROS).
Uric acid is the end product of purine metabolism in humans and has a powerful antioxidant effect. ATP depletion induced by ischemia and intake of fructose and alcohol, as well as degradation of RNA and DNA induced by cell turnover and intake of a purine-rich diet, can activate the purine metabolism pathway.
The most pharmacologically established mechanism of action for methylxanthines as a class is adenosine receptor antagonism. Due to structural similarity with purine nucleosides, caffeine, theophylline, and theobromine can act as competitive inhibitors of adenosine receptors. Acting as adenosine receptor antagonists, these agents stimulate central respiratory drive and improve diaphragmatic contractility.
Derivatives of xanthine (known collectively as xanthines) are a group of alkaloids commonly used for their effects as mild stimulants and as bronchodilators. In contrast to other, more potent stimulants like sympathomimetic amines, xanthines mainly act to oppose the actions of adenosine and increase alertness in the central nervous system.
Adenosine receptor subtypes are pharmacologically distinct targets: adenosine and its agonists regulate the activity of adenylate cyclase through activation of all four adenosine receptors; activation of A1 and A3 lead to Gi-mediated inhibition of adenylate cyclase, while activation of A2A and A2B lead to Gs-mediated activation, with the activation of adenylate cyclase further increasing the concentration of cAMP, a second messenger that plays a vital role in various cellular functions. In pathophysiological conditions, the activation of A1 and A3 receptors can be detrimental for normal cellular functioning.
The pharmacological actions of methylxanthines such as theophylline and caffeine may be due to blockade of adenosine receptors and/or inhibition of phosphodiesterase (PDE) activities. Methylxanthines increase cAMP levels through the inhibition of PDEs. By preventing the breakdown of cyclic nucleotides (cAMP and cGMP), xanthine derivatives potentiate intracellular signaling cascades involved in smooth muscle relaxation, cardiac inotropy, and immune cell function.
The phosphodiesterase inhibition properties of xanthine derivatives have been related to their tracheal relaxant activities. These dual mechanisms — adenosine antagonism and PDE inhibition — operate in parallel and interact with multiple tissue targets simultaneously.
A1 receptor blockade by xanthine derivatives is considered the most probable reason for the diuretic effect of these derivatives, because they act as antagonists of adenosine, which is a key regulator of kidney function by regulating the level of glomerular filtration rate, medullary blood flow, and renal water and electrolyte transport. Xanthine derivatives acting as A1 receptor antagonists increase renal fluid and Na⁺ excretion by blocking the adenosine receptor. Therefore, diuresis and natriuresis have been observed primarily due to selective A1 receptor blockade, which is caused by inhibition of renal reabsorption.
Xanthine oxidase plays an important role in the catabolism of purines in humans, catalyzing the oxidation of hypoxanthine to xanthine and then the oxidation of xanthine to uric acid. Meanwhile, reactive oxygen species (ROS), including superoxide and H₂O₂, are generated during this process. This ROS-generating activity is physiologically regulated but becomes pathologically relevant in conditions of oxidative stress.
Known molecular mechanisms of methylxanthines include adenosine receptor antagonism, phosphodiesterase inhibition, effects on the cholinergic system, Wnt signaling, histone deacetylase activation, and gene regulation. These compounds are best known for their diverse pharmaceutical applications including cyclic nucleotide phosphodiesterase inhibition, antagonization of adenosine receptors, anti-inflammatory, anti-microbial, anti-oxidant, and anti-tumor activities.
Various xanthine derivatives show neuroprotective effects because of their course of action as phosphodiesterase inhibitors, blockers of adenosine uptake in neurons and glial cells, and antagonists of adenosine receptors. The neuro-active effect of xanthine derivatives increases the survival of brain cells.
This is the area of strongest clinical evidence for xanthine-class compounds, built over more than a century of clinical application. Theophylline is widely used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Naturally occurring methylxanthines like caffeine, theophylline, and theobromine are widely consumed in food, while several non-synthetic methylxanthines are used as pharmaceuticals, in particular in treating airway constrictions. Besides the well-established bronchoprotective effects, methylxanthines are also known to have anti-inflammatory and anti-oxidative properties, mediate changes in lipid homeostasis, and have neuroprotective effects.
Methylxanthines act locally on airways and centrally on respiratory control centers. Caffeine, theophylline, and theobromine are the most known methylxanthines as they are present in coffee, tea, and/or chocolate. The bronchodilatory effect is mechanistically linked to phosphodiesterase inhibition and smooth muscle relaxation. The phosphodiesterase inhibition properties of xanthine derivatives have been related to their tracheal relaxant activities.
Evidence strength: For theophylline in asthma and COPD, the clinical evidence is well-established, supported by decades of randomized controlled trials and regulatory approval. The compound is included in international clinical guidelines for both conditions.
Apnea of prematurity affects at least 85% of infants born before 34 weeks' gestation and represents a significant clinical challenge in neonatal intensive care. Methylxanthines, including caffeine, theophylline, and aminophylline, have emerged as the primary pharmacological intervention for this condition. Caffeine citrate has become the preferred therapy owing to its longer half-life, wider therapeutic window, and superior safety profile compared to theophylline and aminophylline.
Since the landmark Caffeine for Apnea of Prematurity (CAP) trial, methylxanthine therapy has been widely implemented. This represents one of the highest levels of clinical evidence for any xanthine-class application in a specific patient population.
Evidence strength: Strong — supported by large randomized controlled trials including the CAP trial, meta-analyses, and systematic reviews; incorporated into standard neonatal intensive care practice.
Xanthine is the immediate metabolic precursor to uric acid, placing it mechanistically at the center of gout pathophysiology. Xanthine oxidase catalyzes the sequential hydroxylation of hypoxanthine to uric acid via xanthine as intermediate. Deposition of crystals of the catalytic product uric acid or its monosodium salt in human joints with accompanying joint inflammation is the major cause of gout.
Plasma hypoxanthine and xanthine were found to be increased in patients with gout compared with control subjects. Urinary hypoxanthine and xanthine levels were reduced in gouty patients compared with controls, whereas levels were increased in patients with uric acid overproduction. A positive correlation was found between the renal clearances of uric acid, hypoxanthine, and xanthine. These results indicate that the renal excretion of hypoxanthine and xanthine is severely impaired in most patients with primary gout.
Drugs targeting the xanthine oxidoreductase enzyme — particularly allopurinol and febuxostat — have been evaluated in large clinical trials. A comprehensive review critically examined the available clinical evidence supporting the treatment of chronic hyperuricemia with xanthine oxidase inhibitors. Although new urate-lowering drugs appear particularly efficacious for acute treatment of refractory hyperuricemia, their use is supported by relatively small clinical evidence. In contrast, large long-term clinical trials have demonstrated that xanthine oxidase inhibitors (allopurinol and febuxostat) are effective and safe.
Treatment with an XOR inhibitor can decrease uric acid for preventing gout, reduce production of XO-related reactive oxygen species, and promote reutilization of hypoxanthine and ATP production through the salvage pathway.
Evidence strength: The role of xanthine in gout pathophysiology is firmly established biochemically. The clinical evidence for xanthine oxidase inhibitors (allopurinol and febuxostat) in managing hyperuricemia and gout is strong, based on large RCTs, though the evidence for broader cardiovascular risk reduction through XOR inhibition remains uncertain.
Xanthine urolithiasis is an infrequent type of renal stone formation caused by xanthinuria, a rare hereditary disorder. An affected patient has a deficiency of xanthine oxidase, resulting in hypouricemia and hypouricosuria. Xanthine calculi are uncommonly encountered stones that, when they occur, typically do so in association with inborn metabolic disorders such as hereditary xanthinuria or Lesch-Nyhan syndrome. They may also occur in association with states of profound hyperuricemia such as myeloproliferative disease after treatment with allopurinol.
There is a genetic disease of xanthine metabolism, xanthinuria, due to deficiency of the enzyme xanthine oxidase. In approximately half of affected patients, ultrasonography reveals the presence of xanthine urolithiasis. There is currently no definitive treatment. Low-purine diet and high fluid intake are recommended.
In vitro evidence suggests a potentially protective role for theobromine metabolites: two inhibitors of xanthine crystallization — 7-methylxanthine and 3-methylxanthine — are major metabolites of theobromine. After theobromine consumption, 21.5% is excreted in urine as 3-methylxanthine and 36% as 7-methylxanthine. Thus, consumption of theobromine could protect patients with xanthinuria from the development of renal xanthine calculi, though clinical trials are necessary to demonstrate these effects in vivo.
Evidence strength: The pathophysiology is biochemically and genetically well-characterized. However, the evidence for theobromine as a protective agent against xanthine stone formation remains preliminary and in vitro only, with no completed human clinical trials reported.
Xanthine oxidoreductase is a target of drugs against gout and hyperuricemia, and the protein is of major interest as it is associated with ischemia reperfusion injury, vascular disorders in diabetes, cardiovascular disorders, adipogenesis, metabolic syndrome, cancer, and many other disease conditions.
In human cells, the metabolism of purine bases generates hypoxanthine, which is converted to uric acid in a two-step process catalyzed by xanthine oxidase. During this process, there is production of reactive oxygen species (ROS), including H₂O₂ and superoxide, which in excess may reduce the production of nitric oxide, leading to endothelial dysfunction. Endothelial dysfunction, characterized by vasoconstriction, thrombogenicity due to activation of platelets, and smooth muscle proliferation, is an important step in the promotion of atherosclerosis, thrombosis, and hypertension. ROS may also reduce myocardial contractility, leading to heart failure, and are implicated in ischemia-reperfusion injury.
There is evidence suggesting that high levels of uric acid represent an independent cardiovascular risk factor and that the use of xanthine oxidase inhibitors may reduce the risk of major adverse cardiovascular events. However, although the relationship between hyperuricemia and hypertension as well as between XOR activity and cardiovascular disease is confirmed, in spite of the increasing number of clinical studies investigating the outcomes of cardiovascular patients treated with urate-lowering therapies, the results are still uncertain.
Evidence strength: The mechanistic link between xanthine oxidase activity, ROS generation, and cardiovascular risk is well-supported by preclinical and observational data. Whether XOR inhibition yields clinically meaningful cardiovascular benefits beyond uric acid lowering remains unresolved in controlled trials, and the evidence is currently mixed.
The hypothesis that xanthine oxidase is a major source of ROS following ischemia-reperfusion injury was initially proposed to explain the enhanced vascular permeability response to reperfusion in cat small intestine following a period of low-flow ischemia. The hypothesis proposed that ischemic insult results in depletion of the energy charge of the cell, an accumulation of hypoxanthine from the catabolism of ATP, and a concomitant conversion of the XDH isoform to XO. With the restoration of blood flow and tissue oxygen tension at reperfusion, it was predicted that the readmitted oxygen and accumulated hypoxanthine would react with XO to produce a burst of superoxide.
Xanthine oxidase serves as a major source of reactive oxygen species during ischemia-reperfusion. Allopurinol and febuxostat, as xanthine oxidase inhibitors, primarily exert protective effects by inhibiting the activity of xanthine oxidase and reducing ROS generation, thereby suppressing oxidative stress damage. Additionally, these inhibitors may improve tissue survival through other mechanisms, such as modulating inflammatory responses and suppressing apoptosis.
Evidence strength: The role of xanthine oxidase in ischemia-reperfusion injury is well-supported by in vitro and animal model evidence. Human clinical evidence for therapeutic XOR inhibition in reducing ischemia-reperfusion outcomes remains limited and ongoing.
By affecting several pathways associated with neurodegenerative diseases via different pleiotropic mechanisms and due to its moderate side effects, intake of methylxanthines has been suggested as an interesting approach in dealing with neurodegeneration. Methylxanthine-regulated genes were found in pathways involved in processes including oxidative stress, lipid homeostasis, signal transduction, transcriptional regulation, as well as pathways involved in neuronal function.
In the context of Alzheimer's disease, methylxanthines including caffeine, theophylline, theobromine, pentoxifylline, and propentofylline have been investigated for their effects on gene expression. Multivariate analysis revealed different or inverse effects on gene regulation for caffeine compared to the other methylxanthines.
Evidence strength: Evidence is preliminary. Most data derives from cell culture and animal models. Large-scale human clinical trials specifically targeting neurodegenerative disease with xanthine derivatives as primary interventions have not yet produced conclusive results.
XOR activity in adipose tissue is low in humans unlike in rodents, and hypoxanthine is secreted from human adipose tissue. The concentration of hypoxanthine, but not xanthine, is independently associated with obesity in a general population, indicating differential regulation of hypoxanthine and xanthine.
Furthermore, gout and hyperuricemia are associated with chronic diseases such as hypertension, diabetes mellitus, metabolic syndrome, and renal and cardiovascular disease. The mechanistic interconnection is through XOR-mediated ROS production and its downstream inflammatory effects on adipose and vascular tissue.
Evidence strength: Mechanistic and epidemiological associations are established, but causal clinical evidence that xanthine modulation per se improves metabolic outcomes in humans is limited.
Methylxanthines are metabolized in the liver predominantly by the enzyme CYP1A2. The microsomal metabolism of caffeine and its primary dimethylxanthine metabolites — paraxanthine, theophylline, and theobromine — has been investigated in human livers. At least two distinct enzymes with differing substrate affinities have the potential to catalyze most methylxanthine N-demethylations and C8-hydroxylations in vitro; however, at the low methylxanthine concentrations routinely encountered in vivo, participation by the high affinity site is expected to predominate.
Theophylline's urinary metabolic profile has been characterized in detail: only 7–12% of theophylline is excreted unchanged in the urine, while several parallel pathways produce 9–18% 3-methylxanthine, 0.3–4% 1-methylxanthine, traces of 3-methyluric acid, 13–26% 1-methyluric acid, and the main metabolite, 1,3-dimethyluric acid, at 35–55%. Allopurinol, a xanthine oxidase inhibitor, increased 1-methylxanthine excretion and decreased 1-methyluric acid excretion, demonstrating that the conversion is mediated by xanthine oxidase.
Methylation of theophylline into caffeine is the predominant metabolic pathway in neonates because the other enzymatic systems are immature. Methylation occurs to some extent in adults, but caffeine does not accumulate because it is metabolized further. The elimination half-life of theobromine is between 6 and 8 hours.
Xanthine itself is not used therapeutically as a stand-alone supplement or pharmaceutical agent. Its methylated derivatives are the clinically and commercially relevant forms. The following represent doses as documented in the cited scientific literature:
Methylxanthines are metabolized in the liver predominantly by the enzyme CYP1A2. Their co-administration with CYP1A2 inhibitors may lead to pharmacokinetic interactions. Methylxanthine fractions have been shown to inhibit CYP3A4 in a concentration-dependent manner in vitro. Concomitant consumption of green tea with CYP3A4 substrates could increase the possibility of interactions, and this requires further clarification.
It has been suggested that discontinuation of an XOR inhibitor causes adverse cardiovascular outcomes as an XOR inhibitor withdrawal syndrome, possibly due to cardiac disturbance of conduction and contraction by reduced ATP production. This is a newly characterized pharmacological phenomenon that remains under active investigation.
Allopurinol, a xanthine oxidase inhibitor, increases 1-methylxanthine excretion and decreases 1-methyluric acid excretion, demonstrating that the conversion is mediated by xanthine oxidase. Clinically, allopurinol therapy can result in accumulation of xanthine and hypoxanthine intermediates, with implications for xanthine stone formation in susceptible individuals. Xanthine calculi may occur in association with states of profound hyperuricemia such as myeloproliferative disease after treatment with allopurinol.
Xanthine is known to cause interference with dipyridamole-thallium-201 myocardial imaging. This is clinically relevant, as patients consuming caffeine-containing products (which are metabolized to xanthine) may have attenuated pharmacological stress test responses.
Normally, xanthine oxidase breaks down the purine base xanthine to uric acid, which is then excreted. In the absence of the enzyme, xanthine is not metabolized by the body and its concentration builds up in the blood and urine. These findings underline the need to add xanthinuria to the list of possible causes of hematuria, persistent urinary tract infection, or acute or chronic kidney failure in adults and children.
Xanthine oxidase-derived ROS have an established pathological role in multiple settings. Oxidative stress resulting from the generation of reactive oxygen species, including superoxide, hydrogen peroxide, and peroxynitrite, occurs during the course of brain ischemia-reperfusion injury. It has been demonstrated that ROS are directly involved in the oxidative damage to cellular macromolecules, such as proteins, lipids, and nucleic acids, in ischemic tissues, leading to cell death.
It has recently been suggested that discontinuation of an XOR inhibitor causes adverse cardiovascular outcomes as XOR inhibitor withdrawal syndrome, possibly due to cardiac disturbance of conduction and contraction by reduced ATP production. This represents an evolving area of pharmacovigilance.
The apparent lack of mutagenic activity of theophylline and other methylxanthines in humans may be due to the fact that the antimitotic threshold is the same as the mutagenic threshold, so that any mutant cells produced are unable to reproduce; the net effect is therefore non-mutagenicity in practice.
Methylation of theophylline into caffeine is the predominant metabolic pathway in neonates because the other enzymatic systems are immature. This has clinical implications for dosing of methylxanthines in preterm infants. Caffeine citrate has become the preferred therapy for apnea of prematurity owing to its longer half-life, wider therapeutic window, and superior safety profile compared to theophylline and aminophylline.
Patients with decompensated liver cirrhosis have different patterns of urinary metabolites of theophylline than healthy subjects, indicating that liver disease significantly alters the pharmacokinetics of xanthine derivatives and may result in unexpected accumulation.
Xanthines are available from various routes including natural sources, biotransformation, transmethylation, and chemical synthesis, each with corresponding advantages. Xanthine derivatives are best known for their pharmaceutical applications including phosphodiesterase inhibition, adenosine-antagonizing activity, and activation of histone deacetylase.
N1, N3, and C8 substitutions together are the most promising sites of substitution on the xanthine scaffold for generating compounds with selective potency toward subtypes of adenosine receptors. Along with adenosine antagonism, xanthine derivatives with C8 substitution are also reported as PDE inhibitors, Topoisomerase II inhibitors, dipeptidyl peptidase 4 inhibitors, and acetylcholinesterase (AChE) inhibitors.
Xanthine derivatives have been exploited in various therapeutic applications such as adenosine receptor antagonists, inducers of histone deacetylase activity, antitumor drugs, anti-asthmatic drugs, and psycho-stimulant drugs. The broader pharmaceutical applications of natural xanthine derivatives have prompted medicinal chemists and pharmaceutical companies to develop more specific compounds using synthetic methodologies.
In pharma, doxofylline (7-(1,3-dioxolan-2-ylmethyl) theophylline), a 1,3,7-tri-substituted xanthine derivative, has been proved to be a good therapeutic molecule. The mode of action of doxofylline differs from theophylline because of substitution at the N7 position with a dioxolane group in the molecular structure. Like theophylline it acts as a phosphodiesterase inhibitor, but it shows poor antagonist activities for adenosine A1 and A2 receptors. Doxofylline may participate in reducing various side effects such as gastric acid secretion.
Health conditions that Xanthine may help support.
Body systems that Xanthine may help support.
Go back